Cell Biotech Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seoul Korea, Republic of (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2009
NCT01088971
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Cell Biotech Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Irritable Bowel Syndrome (Phase 3)

Syndrome (Phase 3)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 9